Medical Access and Reimbursement in Malaysia

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Enforcement and policy are governed under the Dangerous Drugs Act 1952 and national drug-control agencies; national education and anti‑drug materials explicitly list psilocybin/psilocin among hallucinogens of concern. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA/ecstasy is identified in national materials on amphetamine‑type stimulants and treated as an illicit stimulant under Malaysia's drug control framework. # #

Esketamine nasal spray (SPRAVATO) is a registered medicinal product in Malaysia and is available through authorised health‑care providers/distributors; registration appears on Malaysia's regulatory product database (QUEST/NPRA) and is documented in Malaysian prescribing references. Availability: SPRAVATO is listed in Malaysian product registries (QUEST 3+) and in local drug compendia (MIMS Malaysia), indicating regulatory approval for medical use in indicated populations. # # Regulatory oversight: use and distribution fall under the National Pharmaceutical Regulatory Agency (NPRA) / Drug Control Authority processes; clinicians must follow product labelling and NPRA/DCA requirements for a prescription medicine. # Indications and reimbursement: SPRAVATO's local product information mirrors internationally accepted indications — as an adjunct with an oral antidepressant for adults with treatment‑resistant major depressive disorder and for depressive symptoms with acute suicidal ideation/behaviour — but access in Malaysia is routed through specialist clinics and private hospitals. Public (MOH) hospital formularies and universal public reimbursement do not routinely cover SPRAVATO; access is typically through private specialist psychiatry services and hospital clinics where treatment is paid by private insurance (subject to insurer policy) or out‑of‑pocket. There is limited public documentation of nationwide public‑sector reimbursement for esketamine; clinicians and patients should confirm coverage with the specific hospital/insurer and follow NPRA/DCA prescribing requirements. # Clinical delivery requirements: local clinical practice aligns with international safety requirements (supervised administration, monitoring of blood pressure and dissociation, controlled observation period after dosing) as described in the product prescribing information. #

Ketamine is a controlled medicine in Malaysia (used medically as an anaesthetic and analgesic) but its use as a psychiatric/‘psychedelic’ treatment is generally off‑label and provided on a case‑by‑case basis in clinical or private practice settings. Nationally, ketamine is subject to control under the Dangerous Drugs Act and is recognised in national drug information as a dissociative/ketamine substance; law enforcement seizures demonstrate strict controls on diversion and trafficking. # # Clinical use and reimbursement: medically, ketamine is available in hospital settings (general anaesthesia, emergency medicine) and is sometimes used off‑label by psychiatrists and private clinics for treatment‑resistant depression or acute suicidal ideation; such psychiatric use is not a uniformly funded public‑sector option. Public reimbursement through the Ministry of Health (MOH) hospital formularies for ketamine as an antidepressant is not standardised — access is mostly via private clinics, private hospitals, or specific institutional protocols where costs are borne by the patient or private insurer if covered by policy. Practitioners using ketamine for psychiatric indications should follow institutional governance, informed‑consent processes and any NPRA/DCA guidance related to off‑label prescribing. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. National materials list DMT among hallucinogens that are illegal to possess, manufacture, or distribute. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 5‑MeO‑DMT is treated as an illicit hallucinogen under Malaysia’s drug‑control framework. # #

Currently classified as a strictly controlled/unauthorised substance under national drug frameworks, with no authorised medical use outside of approved clinical research. There is no recognised pathway for medical ibogaine treatment in Malaysia. #

Currently classified as a strictly controlled substance under national drug scheduling laws (the active ingredient DMT and related constituents are controlled), with no authorized medical or ceremonial exemption outside approved research. Ceremonial/ritual use would be treated under the same prohibitions as possession or distribution of controlled hallucinogens. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline and cactus species containing mescaline are treated as illegal hallucinogens under Malaysia’s drug control regime. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Novel phenethylamines (the 2C family) are treated as illicit psychotropic substances and fall under enforcement priorities for synthetic/novel psychoactive substances. # #